Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Neuropharmacology. 2016 Apr 13;108:316–323. doi: 10.1016/j.neuropharm.2016.04.013

Fig. 5.

Fig. 5

Effects of JNK/p38MAPK/MEK inhibitors SP600125, SB203580, and PD98059, respectively, on the inhibitory action of tozasertib on neurobehavioral deficits, brain edema and CC-3 at 24 hours after SAH. A, B, JNK/p38MAPK inhibitors significantly inhibited the positive effects of tozasertib on modified Garcia and beam balance score. The MEK inhibitor did not significantly inhibit above mentioned effects. C, JNK/p38MAPK inhibitors obviously inhibited the positive effects of tozasertib on brain edema in left and right hemispheres of the brain. The MEK inhibitor did not obviously inhibit above mentioned effects. D, In the presence of tozasertib and after SAH, CC-3 level was reduced by tozasertib. JNK/p38MAPK/MEK inhibitors countered the inhibitory effect of tozasertib on CC-3 expression in the left cortex. Top, Representative western blots. Bottom, Quantitative analysis of CC-3. *p<0.05 vs SAH+tozasertib+vehicle, #p > 0.05 vs SAH+tozasertib+SP600125/SAH+tozasertib+SB203580.